“Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s118. doi:10.25251/skin.7.supp.118.